Sanofi (SNY)
Pre-market:
- GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrol
- GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeksNearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week Paris and Tarrytown, N.Y. March 18, 2023. Positive results from the clinical trial assessing Dup
- Yahoo Finance Video
Sanofi becomes latest to cut insulin prices, joins Novo Nordisk, Eli Lilly
Yahoo Finance’s Anjalee Khemlani joins the Live show to report that Sanofi has become the latest major drug company to slash insulin prices, capping the cost at $35.
